- cafead Oct 12, 2022 at 11:12: AM
via
article source
- Biogen and Eisai are expecting accelerated approval for an Alzheimer's disease drug in January.
- Gilead Sciences is waiting for approval of a new HIV treatment that only needs to be taken twice a year.
- Mirati Therapeutics could earn approval for an experimental lung cancer drug similar to one that is already generating hundreds of millions annually for Amgen.
article source